Global ophthalmics Leverage Sentiss’s established global footprint across India, USA, Europe, Dubai, Russia and Central Asia to pursue international contract manufacturing, licensing partnerships, and co-development opportunities in ophthalmic products and sterile eye care formulations.

Strong manufacturing moat Capitalize on Sentiss’s two sterile manufacturing facilities in India and Switzerland, plus the US FDA approved sterile facility from the Akorn acquisition, to position as a reliable supplier of high-quality eye drops and ointments for global distributors and private-label programs.

R&D and innovation Target partnerships around innovative eye care products and generics leveraging Sentiss’s state-of-the-art R&D center to accelerate pipeline commercialization, especially for sterile ophthalmic therapies and niche formulations.

CSR and credibility Highlight Sentiss’s CSR leadership and Great Place to Work certification in conversations with potential customers and partners, using these credentials to differentiate in sustainability-minded procurement and collaboration decisions.

Financial scale With revenue in the range of one to ten billion, position Sentiss as a capable partner for larger distribution agreements, regional market expansions, and long-term supply contracts, while exploring opportunities in high-growth ophthalmic segments.